The World Health Organization spokesperson Fadéla Chaib acknowledged undisclosed issues had delayed its emergency use authorization of Russia’s Sputnik V COVID-19 vaccine. Chaib added that the WHO was working through the issues while Russian Health Minister Mikhail Murashko recently said Russian officials were completing the final paperwork needed for the filing. Meanwhile, European Union officials…
Russia reports 91.6% efficacy for its Sputnik V COVID-19 vaccine
The Sputnik V COVID-19 vaccine could be more efficacious than those from AstraZeneca (LON:AZN) or Johnson & Johnson (NYSE:JNJ) based on interim trial results. The two-dose Sputnik vaccine was 91.6% effective at preventing symptomatic COVID-19 and 100% effective at preventing severe and moderate disease in a study involving 19,866 participants. The data were published in The Lancet. No…
Studies to investigate combining AstraZeneca and Sputnik-V COVID-19 vaccines
As things stand now, the Pfizer-BioNTech (NYSE:PFE) and Moderna (NYSE:MRNA) vaccine candidates have broken away from the pack of other vaccine contenders. Both offer efficacy in the range of 95% and are inching toward emergency authorization in the U.S. and elsewhere. But AstraZeneca (LON:AZN) and Russia’s Sputnik-V lab, the Gamaleya Research Institute, are hooking up with the hopes…
Report: Russia hits pause on Sputnik-V COVID-19 vaccine trial
Russia is temporarily tapping the brakes on its Phase 3 COVID-19 vaccine trial as demand for its Sputnik-V vaccine surges, according to several clinical officials quoted by Reuters. Crocus Medical, a company helping administer the vaccine, denies there is a shortage of the vaccine. “Trials are ongoing, and there is sufficient vaccine supply,” said Alexey Butylin,…